Two ongoing clinical studies are part of a programme called FIBRONEER. The FIBRONEER studies are testing the drug BI 1015550 as a treatment for people with idiopathic pulmonary fibrosis (IPF) and people with progressive pulmonary fibrosis (PPF).IPF is a severe lung disease where scar tissue builds up in the lungs. The ‘idiopathic’ part means that doctors do not know the cause of the lung scarring. PPF is a general term to describe the worsening of lung scarring in any disease where scar tissue forms in the lungs, both from known causes such as other underlying diseases and for unknown reasons. While IPF can be considered to be a typical form of worsening lung scarring, in clinical studies, IPF and PPF are usually considered separately. In both IPF and PPF, scar tissue builds up in the lungs, making them smaller and no longer able to take in oxygen well. This leads to difficulty in breathing and getting oxygen to the tissues, making it difficult to perform daily activities and reducing the patient’s quality of life.This Plain Language Summary of Publication article (PLSP) from Future Rare Diseases focuses on a severe lung disease known as idiopathic pulmonary fibrosis (IPF), IPF is a type of lung disease where scar tissue builds up in the lungs. ‘Idiopathic’ means that the doctors do not know the cause of the lung scarring. Progressive pulmonary fibrosis (PPF), is a term that describes the worsening of lung scarring in any disease. This PLSP summarises the results of two ongoing clinical studies that are part of a program called FIBRONEER. The studies tested whether the medication BI 1015550 could be a treatment for people with IPF and PPF.

Visit the Future Medicine using the link to read the article.

This PLSP is based on two original articles. The first original article is called ‘Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with idiopathic pulmonary fibrosis (FIBRONEER-IPF)’ and was published in BMJ Journals.

Visit The BMJ Open Respiratory Research site using the link to read the article.

The second original article is called ‘Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD) ‘ and was published in BMJ Journals.

Visit The BMJ Open Respiratory Research site using the link to read the article.